Mohs Micrographic Surgery With Melanocytic Immunostains for T1a/b Invasive Melanoma Yields <1% Local Recurrence and Disease-specific Mortality.

IF 2.5 3区医学 Q2 DERMATOLOGY Dermatologic Surgery Pub Date : 2025-02-01 Epub Date: 2024-09-30 DOI:10.1097/DSS.0000000000004414

Anagha Bangalore Kumar, Thomas Trischman, Eucabeth Asamoah, Austin Todd, Nahid Y Vidal, Addison M Demer

{"title":"Mohs Micrographic Surgery With Melanocytic Immunostains for T1a/b Invasive Melanoma Yields <1% Local Recurrence and Disease-specific Mortality.","authors":"Anagha Bangalore Kumar, Thomas Trischman, Eucabeth Asamoah, Austin Todd, Nahid Y Vidal, Addison M Demer","doi":"10.1097/DSS.0000000000004414","DOIUrl":null,"url":null,"abstract":"Background: The use of Mohs micrographic surgery with melanocytic immunostains (MMS-I) for cutaneous melanoma is increasing.Objective: To assess local recurrence, melanoma-specific death rates in patients with invasive melanoma treated with MMS-I.Materials and methods: A single-center retrospective review of patients with invasive melanoma treated with MMS-I from January 2008 to December 2018.Results: Three hundred fifty-two patients (359 melanomas) were included. The median age was 71 years; most patients were male (252%; 71.6%). Most tumors were T1a/b (341, 95%), H/N (322; 89.7%), and lentigo maligna subtype (281, 78.3%). At a median follow-up of 4.3 years, local recurrence rates were 1.4% (5) and 0.9% (3) among all-stage and T1a/b tumors, respectively. There were 3 melanoma-related deaths (0.9%).Conclusion: MMS-I is associated with <1% risk of local recurrence and disease-specific mortality for T1a/b melanomas.","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"123-126"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DSS.0000000000004414","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The use of Mohs micrographic surgery with melanocytic immunostains (MMS-I) for cutaneous melanoma is increasing.

Objective: To assess local recurrence, melanoma-specific death rates in patients with invasive melanoma treated with MMS-I.

Materials and methods: A single-center retrospective review of patients with invasive melanoma treated with MMS-I from January 2008 to December 2018.

Results: Three hundred fifty-two patients (359 melanomas) were included. The median age was 71 years; most patients were male (252%; 71.6%). Most tumors were T1a/b (341, 95%), H/N (322; 89.7%), and lentigo maligna subtype (281, 78.3%). At a median follow-up of 4.3 years, local recurrence rates were 1.4% (5) and 0.9% (3) among all-stage and T1a/b tumors, respectively. There were 3 melanoma-related deaths (0.9%).

Conclusion: MMS-I is associated with <1% risk of local recurrence and disease-specific mortality for T1a/b melanomas.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用黑色素细胞免疫标记对 T1a/b 侵袭性黑色素瘤进行莫氏显微摄影手术，局部复发率和疾病特异性死亡率均小于 1%。

背景：使用带有黑色素细胞免疫标记（MMS-I）的莫氏显微外科手术治疗皮肤黑色素瘤的患者越来越多：评估采用MMS-I治疗的浸润性黑色素瘤患者的局部复发率和黑色素瘤特异性死亡率：对2008年1月至2018年12月接受MMS-I治疗的浸润性黑色素瘤患者进行单中心回顾性研究：共纳入352例患者（359例黑色素瘤）。中位年龄为71岁；大多数患者为男性（252%；71.6%）。大多数肿瘤为T1a/b（341例，95%）、H/N（322例，89.7%）和恶性扁平苔藓亚型（281例，78.3%）。中位随访时间为4.3年，全期和T1a/b期肿瘤的局部复发率分别为1.4%（5例）和0.9%（3例）。有3例黑色素瘤相关死亡（0.9%）：结论：MMS-I与

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Dermatologic Surgery 医学-皮肤病学

CiteScore

3.10

自引率

16.70%

发文量

547

期刊介绍： Exclusively devoted to dermatologic surgery, the Dermatologic Surgery journal publishes the most clinically comprehensive and up-to-date information in its field. This unique monthly journal provides today’s most expansive and in-depth coverage of cosmetic and reconstructive skin surgery and skin cancer through peer-reviewed original articles, extensive illustrations, case reports, ongoing features, literature reviews and correspondence. The journal provides information on the latest scientific information for all types of dermatologic surgery including: -Ambulatory phlebectomy- Blepharoplasty- Body contouring- Chemical peels- Cryosurgery- Curettage and desiccation- Dermabrasion- Excision and closure- Flap Surgery- Grafting- Hair restoration surgery- Injectable neuromodulators- Laser surgery- Liposuction- Microdermabrasion- Microlipoinjection- Micropigmentation- Mohs micrographic surgery- Nail surgery- Phlebology- Sclerotherapy- Skin cancer surgery- Skin resurfacing- Soft-tissue fillers. Dermatologists, dermatologic surgeons, plastic surgeons, oculoplastic surgeons and facial plastic surgeons consider this a must-read publication for anyone in the field.